Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Region of Southern Denmark | OTHER |
| Odense Patient Data Explorative Network | OTHER |
| University of Southern Denmark | OTHER |
| Nordisk Rebalance A/S |
Not provided
Not provided
Not provided
Not provided
Investigators wishes to influence the gut microbiota in patients with alcoholic liver disease in a randomized controlled clinical trial. The investigators hypothesize that the alcohol-related dysbiosis seen in these patients can be changed and disease progression haltered by modulating microbiota with probiotics during 24 weeks.
Chronic alcohol overuse is associated with increased gut permeability and in addition, the intestinal microbiota changes qualitatively (dysbiosis) and quantitatively (bacterial overgrowth) in alcoholic liver disease in favour of a microbiota with increased invasive potential. As a consequence, an increased load of bacterial products is transported to the liver leading to inflammation and fibrogenesis.
This cross talk between the intestinal microbiota and the liver constitute a gut-liver axis, which is increasingly recognized as key mechanism in the progression of liver disease and pathogenesis of liver related complications.
The investigators hypothesize that the gut microbiota and its metabolites are major drivers of fibrosis in human liver disease and that modulating the intestinal flora by Profermin® (a food for special medical purposes) will modulate the alcohol related dysbiotic signatures in the microbiota which may halter disease progression by reducing activity of hepatic stellate cells.
Dietary supplements that alter the microbiome towards a more beneficent type may improve liver inflammation and thus be a better alternative than supplements that simply add nutrients. Investigators expect that the trial will provide proof-of-concept for a sustainable dietary strategy in liver fibrosis.
Examples of biopsies which did not meet quality criteria for reliable histological reading, led to inclusion of 16 extra patients. In total we included 56 patients to ensure an adequate number of participants with valid liver biopsy data for assessment of the primary endpoint and intention-to-treat analysis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Profermin Plus® | Experimental | Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases. |
|
| Fresubin® | Active Comparator | Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Profermin Plus, FSMP, probiotics | Dietary Supplement | Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks. The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed. |
| Measure | Description | Time Frame |
|---|---|---|
| Hepatic stellate cell activity | Attenuation of liver hepatic stellate cell activity, defined as the proportion of patients with a 10% or more reduction in activated hepatic stellate cells, measured by a-smooth muscle actin (a-SMA) stain quantification of liver biopsies. | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Hepatic a-SMA activity | Reduction in hepatic a-SMA activity | 24 weeks |
| Hepatic inflammation | Evaluated by hepatic inflammation markers and metabolites |
Not provided
Inclusion Criteria:
Prior or ongoing harmful alcohol intake defined as an average of ≥24g alcohol/day for women and ≥36g/d for men for ≥ 5 year.
Outpatients with compensated advanced chronic alcohol-related liver disease, defined as stable patients with:
Understand and speak Danish written and orally
Informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| FLASH - Centre of Liver Research | Odense | Fyn | 5000 | Denmark | ||
| Odense University Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| INDUSTRY |
Patients will be randomized 1:1 to receive Profermin Plus® versus a general FSMP, Fresubin®, for 24 weeks.
Not provided
Not provided
Pathologist will perform outcome assessment blinded
Not provided
|
| Fresubin, dietary supplement | Dietary Supplement | Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks. |
|
| 24 weeks |
| Alfa-smooth muscle actin concentration | Reduction in circulating a-smooth muscle actin concentration | 24 weeks |
| Hepatic venous pressure gradient (HVPG) | Reduction in portal pressure measured by the HVPG in unit mmhg | 24 weeks |
| Reduction in non-invasive fibrosis markers | Reduction in Ultrasound shear wave elastography (transient and 2-dimensional) (kPa) | 24 weeks |
| Reduction in non-invasive fibrosis markers | ProC3 and ProC4 (ng/ml) | 24 weeks |
| Reduction in non-invasive fibrosis markers | ELF test | 24 weeks |
| Reduction in non-invasive fibrosis markers | Forns index | 24 weeks |
| Reduction in non-invasive fibrosis marker | APRI score | 24 weeks |
| Reduction in non-invasive fibrosis markers | FIB4 (points) | 24 weeks |
| Markers of liver inflammation | Reduction in circulating markers of liver inflammation (cytokeratin-18 degradation products M30 and M65) | 24 weeks |
| Improvement of liver histological lesions | Improvement in semiquantitative liver histological lesions that fulfil at least one of two criteria:
[Worsening defined as an increase of at least one stage of either lobular inflammation or hepatocyte ballooning. Resolution defined as ballooning=0 and lobular inflammation=0-1] | 24 weeks |
| Improvement in gut dysbiosis | Defined as:
| 24 weeks |
| Liver vein outflow of microbial products | Change in Liver vein outflow of microbial products | 24 weeks |
| Lipid profile | Improvement of lipid profile defined as: Rising HDL, decrease in triglycerids, LDL and total cholesterol | 24 weeks |
| Any changes in non-invasive markers of steatosis | Controlled Attenuation Parameter(CAP) and ultrasonographic steatosis assessment (bright liver echo pattern) | 24 weeks |
| Individual domains of NAS scoring systemt | Any changes in individual domains of the NAS scoring system (fibrosis 0-4, steatosis 0-3, lobular inflammation 0-2, portal inflammation 0-1, ballooning 0-2) or in collagen proportionate area (%) | 24 weeks |
| Metabolic changes | Water soluble metabolites in circulation will be evaluated with metabolomics | 24 weeks |
| Changes in circulating cytokines | Cytokines related to cardiovascular disease and inflammation will be analysed | 24 weeks |
| Changes in hepatic macrophage activity | Changes in digital imaging analysis of hepatic CD163 expression in liver biopsies | 24 weeks |
| Changes in intestinal fibrosis markers | C4M generated by decomposition of type 4 collagen | 24 weeks |
| Changes in intestinal fibrosis markers | CPA9-HNE a fragment degraded from calprotectin | 24 weeks |
| Changes bile acids | Changes in bile acids will be measured in both stool and circulation | 24 weeks |
| Metabolic changes | Amino acids in circulation will be evaluated with metabolomics | 24 weeks |
| Metabolic changes | Lipidomics in circulation will be evaluated with metabolomics | 24 weeks |
| Metabolic changes | Lipidomics in liver samples will be evaluated with metabolomics | 24 weeks |
| Metabolic changes | Short chain fatty acids in circulation will be evaluated with metabolomics | 24 weeks |
| Metabolic changes | Short chain fatty acids in stool samples will be evaluated with metabolomics | 24 weeks |
| Odense |
| 5000 |
| Denmark |
| ID | Term |
|---|---|
| D008108 | Liver Diseases, Alcoholic |
| D008104 | Liver Cirrhosis, Alcoholic |
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D020751 | Alcohol-Induced Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| C048418 | Fresubin |
| D019587 | Dietary Supplements |
| ID | Term |
|---|---|
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
Not provided
Not provided